Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia

Next Previous
X
Search
Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Alzheimer's disease; Dementia; Lewy body disease; Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Axovant Gene Therapies; Axovant Sciences; Sio Gene Therapies [CEASED]

    • Most Recent Events

    • 08 Jan 2018 Results presented in an Axovant Sciences media release.
    • 08 Jan 2018 According to a company media release, Axovant Sciences has decided to discontinue intepirdine program based on negative results from MINDSET, HEADWAY and Gait and Balance studies.
    • 08 Jan 2018 Primary endpoint (Change in quantitative gait measurements from baseline to the end of each double-blind treatment period based on computerized gait assessment tools) has not been met, according to an Axovant Sciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top